BioPharma Dive June 8, 2023
Kristin Jensen

Dive Brief:

  • Upstream Bio has successfully navigated a rocky market for biotech startups to raise $200 million in fresh financing in a Series B round.
  • The company plans to use the funds to advance its experimental medicine UPB-101 into Phase 2 trials for asthma and chronic rhinosinusitis with nasal polyps and is also preparing for “a swift transition to Phase 3 development.” The drug is currently in Phase 1b testing for asthma.
  • Enavate Sciences and Venrock Healthcare Capital Partners led the latest round of financing, which also attracted new investors Bain Capital Life Sciences and Wellington Management. Enavate’s Edd Fleming and Venrock’s Alex Rosen joined Upstream’s board as well, the company said Thursday.

Dive Insight:

Led by Samantha...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
23andMine: CEO Wojcicki aims to take genetics company private
AI That Predicts Targeted Cancer Drug Response with Single-Cell Precision

Share This Article